A variety of cancers over-produce ligands of GPCRs expressed by specific immune cells to shut down their surveillance. It is the case for adenosine via A2a and A2b receptors, but also for prostaglandin E2 ( PGE2 ), produced by COX2 positive tumors, that activates the prostaglandin receptor 4 ( EP4R ). Antagonizing EP4 receptor is therefore a novel therapeutic approach to restore cancer recognition by the immune system and combat its progression.

Program description

EP4 receptor antagonist ( DT-9081 )

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

Domain has designed a small molecule drug candidate DT-9081 which is progressing towards the clinic. Together with tumor profiling, the company has translated a complete and robust biomarker strategy monitoring target engagement and efficacy to support clinical development and cancer type prioritization.

Additional resources

DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties

This poster presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrating a best-in-class potential.

Download file

In order to download this file, please fill the form bellow.

Other programs

Merck is one of Domain Therapeutics’s partners

A2aR/A2bR antagonist


Undisclosed GPCR targets